IPP Bureau
Halozyme wins German injunction blocking Merck’s Keytruda distribution
By IPP Bureau - December 08, 2025
While Merck can appeal, Halozyme said it expects the order to hold
Freenome strikes SPAC deal to go public in 2026
By IPP Bureau - December 08, 2025
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Bengaluru healthtech firm Biomoneta secures USFDA nod for air purifier
By IPP Bureau - December 08, 2025
Captured microbes are then neutralized on engineered microbicidal surfaces
New study aims to improve mobility for millions with flat foot and knee osteoarthritis
By IPP Bureau - December 08, 2025
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Groundbreaking study identifies 250 genes driving ME & long COVID
By IPP Bureau - December 08, 2025
76 of 180 long COVID-associated genes also linked to ME
_Logo.png "Agilus Diagnostics launches comprehensive obesity & metabolic health test suite"){kind=logo}
Agilus Diagnostics launches comprehensive obesity & metabolic health test suite
By IPP Bureau - December 08, 2025
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Praxis Precision hits milestone in fight against rare paediatric seizures
By IPP Bureau - December 08, 2025
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
B Braun unveils ready-to-use antibiotic system
By IPP Bureau - December 08, 2025
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Takeda seals $1.2 billion oncology deal with Innovent Biologics
By IPP Bureau - December 07, 2025
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Bayer advances fight against rare kidney disease with new experimental drug
By IPP Bureau - December 07, 2025
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Bayer launches phase III trial testing Mirena for uterine condition with no treatments
By IPP Bureau - December 07, 2025
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment
By IPP Bureau - December 07, 2025
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Bayer reports promising results for low-dose pediatric MRI contrast agent
By IPP Bureau - December 07, 2025
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon to merge Biocon Biologics in $5.5 billion deal
By IPP Bureau - December 07, 2025
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
